Why the study?
Many systemic anticancer treatments cause cardiotoxicity, making identification of patients at greatest risk a research priority as cancer survival improves.
This review highlights the emerging role of precision medicine in cardio-oncology to identify patients at risk for chemotherapy-induced cardiotoxicity.
Cardiotoxicity risk stratification gains urgency with rising cancer survival; leaves open standardized cardio-oncology protocols.
Cancer and cardiovascular disease are the leading causes of death in the United Kingdom. Many systemic anticancer treatments are associated with short- and long-term cardiotoxicity. With improving cancer survival and an ageing population, identifying those patients at the greatest risk of cardiotoxicity from their cancer treatment is becoming a research priority and has led to a new subspecialty: cardio-oncology. In this concise review article, we discuss cardiotoxicity and systemic anticancer therapy, with a focus on chemotherapy. We also discuss the challenge of identifying those at risk and the role of precision medicine as we strive for a personalised approach to this clinical scenario.
No takes yet. Share an insight, caveat, or question.
Viswanathan et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: